• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

The Association between Hormone Therapy and Cardiovascular Diseases or Type 2 Diabetes

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Kim et al. (Menopause, 2021) investigated the association of menopausal hormone therapy (MHT) with cardiovascular diseases (CVDs) and type 2 diabetes among middle-aged postmenopausal women  

METHODS: 

  • Retrospective cohort study  
    • Data derived from mandatory single-payer program used by entire Korean population 
  • Population 
    • Postmenopausal women  
    • Reported menopause status from the cancer-screening program between 2006 and 2008  
    • Reported age at menopause onset of 40 to 69 years 
    • Had menopause period ≤1 year  
    • Exclusion: Previous diagnostic CVDs, type 2 diabetes, or other diseases associated with contraindication to MHT use (cancer, transient ischemic attack, and liver diseases) 
  • Exposures 
    • Oral MHT: Classified as estrogen only, combined estrogen and progestogen, tibolone, and multitype 
  • Study design 
    • Menopause status: Self-reported  
    • Time-dependent Cox regression modeling was used to evaluate the associations between MHT and the primary outcomes | Multiple potential confounding variables were adjusted for including age at menopause, preexisting comorbidities, socioeconomic status and lifestyle factors  
    • Subgroup analyses: Regimen type | Cumulative duration 
  • Primary outcomes 
    • CVDs 
    • Type 2 diabetes 

RESULTS: 

  • MHT users: 8013 women (13.8%) | MHT nonusers: 50,047 women (86.2%) 
  • MHT category 
    • Combined EP: 24.5% 
    • Tibolone: 43.0% 
    • Estrogen-only: 6.8% 
  • MHT was not significantly associated with CVDs or type 2 diabetes 
    • CVDs: HR 1.085 (95% CI, 0.899 to 1.310) 
    • Type 2 diabetes: HR 1.104 (95% CI, 0.998 to 1.221) 
  • There were no differential effects observed for  
    • Regimen type 
    • Cumulative duration of treatment 
    • Years since menopause  

CONCLUSION: 

  • MHT does not appear to have any effects on CVDs or type 2 diabetes in postmenopausal women 
  • The authors state 

To the best of our knowledge, there have been no studies assessing the associations of MHT with CVDs following the current guidelines or algorithms for MHT 

Our results may suggest that the use of MHT for appropriate participants who have assessed the timing of initiation or baseline diseases can expect relief of menopausal symptoms by MHT without concerns about the risk of CVDs 

Learn More – Primary Sources: 

Effects of menopausal hormone therapy on cardiovascular diseases and type 2 diabetes in middle-aged postmenopausal women: analysis of the Korea National Health Insurance Service Database 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Prospective Data: Breast Cancer Risk and Menopausal Hormone Therapy
The WHI Randomized Trials: Is Menopausal Hormone Therapy Associated with Long-Term Mortality?
Menopausal Hormonal Therapy and Dementia Risk
Hormone Therapy and VTE: Quantifying Risk Based on Preparation and Route of Administration

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site